A Phase 4 interventional study of Aripiprazole in Major Depressive Disorder, sponsored by Taiwan Otsuka Pharm. Co., Ltd. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-05-21.
Sponsored by Taiwan Otsuka Pharm. Co., Ltd (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 9th largest by enrollment, is one of 3 that started in 2011, is one of 11 in phase 4, and was the 19th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:
Peking University · Sites in China
Ages 18–55
Xinyu Zhou · Sites in China
Ages 12–17
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 173 across the 33 interventional studies. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiwan Otsuka Pharm. Co., Ltd, one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiwan Otsuka Pharm. Co., Ltd is the lead sponsor of 7 studies on the registry; none are open to participants now.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 20th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2011, is one of 4 in phase 4, and was the 20th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
1 of the studies testing aripiprazole in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate effectiveness and tolerability of aripiprazole augmentation in outpatients with major depressive disorder who have had inadequate response to antidepressants in Taiwan clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed with major depressive disorder as defined by (DSM-IV), who fulfill both the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aripiprazole
starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
17-Item Hamilton Depression Rating Scale (HAM-D17) score
Primary effectiveness endpoint: - Change from baseline in HAM-D17 score at Week 6 Secondary effectiveness endpoints: 1. Change from baseline in HAM-D17 score at Week 1, 2 and 4 2. Response rate at Week 1, 2, 4 and 6 - Response rate: decrease in HAM-D17 total score of at least 50% 3. Remission rate at Week 1, 2, 4 and 6 - Remission rate: HAMD-17 score ≤ 7
Time frame: Week 1, 2, 4 and 6
Clinical Global Impression of Severity (CGI-S) score
1. Change from baseline in CGI-S score at Week 1, 2, 4 and 6 2. CGI-I score at Week 1, 2, 4 and 6
Time frame: Week 1, 2, 4 and 6
Sheehan Disability Scale (SDS) total score
Change from baseline in SDS total score at Week 1, 2, 4 and 6
Time frame: Week 1, 2, 4 and 6
World Health Organization Quality of Life (WHOQOL-BREF) score
Change from baseline in WHOQOL-BREF score at Week 6
Time frame: Week 6
The record gives a start of Sep 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Taiwan Otsuka Pharm. Co., Ltd →